Toffen Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 2.87 Cr
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2015
- Open Charges ₹ 10.88 Cr
- Revenue Growth -58.84%
- Profit Growth 143.03%
- Ebitda 92.06%
- Net Worth 0.32%
- Total Assets -21.73%
About Toffen Pharmaceuticals
Toffen Pharmaceuticals Private Limited (TPPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 June 2011 and has a history of 13 years and seven months. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2015. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.87 Cr.
The company currently has active open charges totaling ₹10.88 Cr.
Anu Mahajan and Pulkit Mahajan serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100MH2011PTC219139
- Company No.
219139
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jun 2011
- Date of AGM
30 Sep 2015
- Date of Balance Sheet
31 Mar 2015
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Toffen Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anu Mahajan  | Director | 27-Jun-2011 | Current |
| Pulkit Mahajan | Director | 27-Jun-2011 | Current |
Financial Performance of Toffen Pharmaceuticals.
Toffen Pharmaceuticals Private Limited, for the financial year ended 2015, experienced significant reduction in revenue, with a 58.84% decrease. The company also saw a substantial improvement in profitability, with a 143.03% increase in profit. The company's net worth moved up by a moderate rise of 0.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Toffen Pharmaceuticals?
In 2015, Toffen Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹10.88 Cr
₹0
Charges Breakdown by Lending Institutions
- Uco Bank : 10.88 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Mar 2012 | Uco Bank | ₹1.30 M | Open |
| 07 Mar 2012 | Uco Bank | ₹10.75 Cr | Open |
How Many Employees Work at Toffen Pharmaceuticals?
Unlock and access historical data on people associated with Toffen Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Toffen Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Toffen Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
